Lung Cancer Therapeutics Market by Molecules, Disease, Cancer Type, Therapy, Distribution

Description

List of Tables

The Global Lung Cancer Therapeutics Market is forecasted to grow significantly, with a projected USD 25.04 billion in 2023 at a CAGR of 8.37% and expected to reach a staggering USD 44.03 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Lung Cancer Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Lung Cancer Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Molecules, market is studied across Biologics and Small Molecules. The Small Molecules is projected to witness significant market share during forecast period.

Based on Disease, market is studied across NSCLC and SCLC. The SCLC is projected to witness significant market share during forecast period.

Based on Cancer Type, market is studied across Lung Carcinoid Tumor, Non-small Cell Lung Cancer, and Small Cell Lung Cancer. The Small Cell Lung Cancer is projected to witness significant market share during forecast period.

Based on Therapy, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy. The Immunotherapy is further studied across Atezolizumab, Durvalumab, Nivolumab, and Pembrolizumab. The Radiation Therapy is further studied across External Beam, Internal Beam, and Systemic. The Targeted Therapy is further studied across Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, and Osimertinib. The Chemotherapy is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospital Pharmacies, Online Phramacies, and Retail Pharmacies. The Hospital Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Lung Cancer Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Lung Cancer Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Lung Cancer Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Lung Cancer Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Lung Cancer Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Lung Cancer Therapeutics Market?

6. What is the market share of the leading vendors in the Global Lung Cancer Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Lung Cancer Therapeutics Market?

Product Code: MRR-437A5D08AE40

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Lung Cancer Therapeutics Market, by Molecules, 2022 vs 2030
4.3. Lung Cancer Therapeutics Market, by Disease, 2022 vs 2030
4.4. Lung Cancer Therapeutics Market, by Cancer Type, 2022 vs 2030
4.5. Lung Cancer Therapeutics Market, by Therapy, 2022 vs 2030
4.6. Lung Cancer Therapeutics Market, by Distribution, 2022 vs 2030
4.7. Lung Cancer Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increase in prevalence of lung cancer across the globe
  - 5.1.1.2. Growing awareness regarding enhanced health care
  - 5.1.1.3. Rising government initiatives for lung cancer treatment
- 5.1.2. Restraints
  - 5.1.2.1. Huge availability of the generic drugs
  - 5.1.2.2. Reduced life expectancy of patients undertaking lung cancer treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing funding in the field of research and development of new treatment
  - 5.1.3.2. Adoption of advanced therapy such as immunotherapy
- 5.1.4. Challenges
  - 5.1.4.1. Risk of side effects of radiation and chemotherapy
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Lung Cancer Therapeutics Market, by Molecules

6.1. Introduction
6.2. Biologics
6.3. Small Molecules

7. Lung Cancer Therapeutics Market, by Disease

7.1. Introduction
7.2. NSCLC
7.3. SCLC

8. Lung Cancer Therapeutics Market, by Cancer Type

8.1. Introduction
8.2. Lung Carcinoid Tumor
8.3. Non-small Cell Lung Cancer
8.4. Small Cell Lung Cancer

9. Lung Cancer Therapeutics Market, by Therapy

9.1. Introduction
9.2. Chemotherapy
9.3. Immunotherapy
- 9.3.1. Atezolizumab
- 9.3.2. Durvalumab
- 9.3.3. Nivolumab
- 9.3.4. Pembrolizumab
9.4. Radiation Therapy
- 9.4.1. External Beam
- 9.4.2. Internal Beam
- 9.4.3. Systemic
9.5. Targeted Therapy
- 9.5.1. Bevacizumab
- 9.5.2. Dabrafenib/Trametinib
- 9.5.3. Erlotinib Hydrochloride
- 9.5.4. Osimertinib

10. Lung Cancer Therapeutics Market, by Distribution

10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Phramacies
10.4. Retail Pharmacies

11. Americas Lung Cancer Therapeutics Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Lung Cancer Therapeutics Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Lung Cancer Therapeutics Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing